BioCentury
ARTICLE | Distillery Therapeutics

Cancer

October 4, 2018 4:19 PM UTC

Publisher’s note: On Feb. 20, the authors of the Nature paper cited below retracted it due to issues with figure presentation and underlying data.

Mouse studies suggest CAR T cells targeting ALCAM and HER2 could help treat brain cancer. The cells are generated by conjugating T cells expressing HER2-targeting CARs to a construct consisting of pentamers of the extracellular ALCAM-binding domain of CD6 attached to an IgG1 hinge and CD6 transmembrane and signaling domains. In a xenograft mouse model of glioblastoma, the CAR T cells decreased tumor growth and increased survival compared with HER2 CAR T cells lacking the CD6 domains or unmodified T cells. Next steps include clinical testing of the CD6-domain CAR T cells in brain cancer...